ALTME — TME Pharma NV Income Statement
0.000.00%
Last trade - 00:00- €1.45m
- -€1.80m
Annual income statement for TME Pharma NV, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 5.77 | 13.3 | 12 | 5.62 | 5.25 |
| Operating Profit | -5.77 | -13.3 | -12 | -5.62 | -5.25 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -10.4 | -14.5 | -15.1 | -6.73 | -5.72 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -10.4 | -14.5 | -15.1 | -6.74 | -5.72 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -10.4 | -14.5 | -15.1 | -6.74 | -5.72 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -10.4 | -14.5 | -15.1 | -6.74 | -5.72 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -32.3 | -21.9 | -12.9 | -1.24 | -0.132 |